In patients with CIS or MS, IgG-IC inhibited TNF+ cell frequencies regardless of sex (Figures 8C, D), and the effects of blocking CD32b were statistically significant in the analysis including both male and female patients (Figure 8C) and borderline significant in female patients with CIS or MS (Figure 8D). The gene discussed is FCGR2B; the disease is myeloid sarcoma.